LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is initiating a pre-clinical study in collaboration with the Netherlands Cancer Institute to explore the potential of its compound LB-100 in eliminating "initiated" cells that carry mutations associated with cancer [1][2]. Group 1: Study Details - The new study will focus on whether LB-100 can eliminate "initiated" cells with a mutant RAS oncogene in animal models, which could significantly reduce the risk of developing various cancers as individuals age [3]. - The study is part of LIXTE's broader strategy to enhance cancer prevention efforts alongside ongoing clinical trials for ovarian and colorectal cancers [2]. Group 2: Leadership and Expertise - The study will be led by Dr. René Bernards, a prominent figure in molecular carcinogenesis and a member of LIXTE's Board of Directors, highlighting the expertise behind the research [4]. Group 3: Company Background - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, with its lead compound LB-100 showing promise in terms of patient tolerance and low toxicity during Phase 1 clinical trials [5][6]. - LB-100 is positioned as a first-in-class PP2A inhibitor, with potential applications in enhancing chemotherapies and immunotherapies for cancer patients [5].